Ignite Creation Date:
2024-05-05 @ 11:19 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002043
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia PCP in Patients With AIDS-Related Complex ARC
Sponsor:
Jacobus Pharmaceutical
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia PCP in Patients With AIDS-Related Complex ARC
Status:
COMPLETED
Status Verified Date:
1989-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine which of 2 doses of dapsone is effective prophylaxis for Pneumocystis carinii pneumonia PCP in patients with oral thrush or hairy leukoplakia and less than 400 CD4 lymphocytes per mm3 To determine whether the long-term toxicities associated with daily dapsone in this population are tolerable
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: